期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CD20单抗临床应用局限与免疫效应器耗竭的研究进展

Limitations of CD20mAb in clinical applications and effectors exhausting
原文传递
导出
摘要 CD20单克隆抗体(Rituximab),已被批准应用于非霍奇金B淋巴瘤的治疗,并取得了显著的免疫疗效。但在大负荷循环B细胞存在的情况下,由于机体效应器如效应细胞,效应因子的耗竭,继发表面抗原抗体结合物的削片反应,导致了肿瘤的耐药与复发,降低了Rituximab的疗效。此综述通过对近20年来CD20单抗研究现状的阐述,讨论其作用机制及在效应器耗竭方面的局限,探索适宜的改进方法,以拓展其应用前景。 Rituximab,an approved CD20 monoclonal antibody（CD20mAb）,has prominent effects in B-cell non-Hodgkin＇s lymphoma（NHL）.However,the presence of resistance and relapse under high circulatory target B cells burden makes it inefficacious,which may result from antigen antibody complex shaving action based on effectors exhausting,such as effect cells and cytokine.In this review,we expound the research of Rituximab＇s immunotherapy mechanisms and effectors exhausting in the last two decades,trying to explore eligible strategies to expand its application in the future.
作者 温良鹤 徐玉清
机构地区 哈尔滨医科大学附属第二临床医院肿瘤内科
出处 《免疫学杂志》 CAS CSCD 北大核心 2011年第11期992-995,共4页 Immunological Journal
关键词 CD20单抗 非霍奇金B淋巴瘤 效应器耗竭 耐药与复发 改进方法 CD20mAb B-cell NHL Effectors exhausting Resistance and relapse Eligible strategies
分类号 R392-12 [医药卫生—免疫学]
  • 相关文献

参考文献21

  • 1Cheung MC, Haynes AE, Meyer RM, et al. Rituximab in |ymphoma:a systematic review and consensus practiceguideline from cancer care ontario [J]. Cancer Treat Rev, 2007, 33(2): 161-176.
  • 2Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy[J]. J Immunol, 2005, 174(2): 817-826.
  • 3Shiokawa M, Takahashi T, Murakami A, et al. In vivo assay of human NK-dependent ADCC using nod/SClD/gammae (null) (NOG) miee[J]. Bioehem Biophys Res Commun, 2010, 399(4): 733-737.
  • 4Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximah in autoimmune disease--the immune complex decoy hypothesis [J]. Nat Clin Pract Rheumatol, 2007, 3(2): 86-95.
  • 5Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells[J]. Exp Hematol, 2006, 34(6): 753-759.
  • 6Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies [J]. PLoS One, 2007, 2(3): e326.
  • 7范艳莹,付笑迎,尹凌凡,刘昀,吴长有.TLR7/8配体(R848)对人NK细胞杀伤功能的作用及其机制的探讨[J].免疫学杂志,2010,26(8):657-660. 被引量：4
  • 8Di GN, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo [J]. J Immunol, 2003, 171(3): 1581-1587.
  • 9Klepfish A, Schattner A, Ghoti H, et al. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia [J]. Lancet Oncol, 2007, 8(4): 361-362.
  • 10Kumar V, All SR, Konrad S, et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice [J]. J Clin Invest, 2006, 116(2): 512-520.

二级参考文献17

  • 1闫小毅,曹雪涛（审校）.TLR7介导抗病毒免疫应答研究进展[J].国外医学（免疫学分册）,2005,28(5):292-295. 被引量：7
  • 2张家永,李和军,李频,周小玲,郑祥雄.CD40-IgG1Fc融合蛋白真核表达载体的构建及表达[J].福建医科大学学报,2007,41(2):105-108. 被引量：2
  • 3[1]Banchereau J,Bazan F,Blanchard D,et al.The CD40 antigen and its ligand[J].Annu Rev Immunol,1994,12:881-922.
  • 4[2]Laman JD,daassen E,Noelle RJ.Functions of CD40 and its ligand,gp39(CD40L)[J].Crit Rev Immunol,1996,16(1):59-108.
  • 5[3]Howard LM,Miller SD.Immunotherapy targeting the CD40/ CD 154 costimulatory pathway for treatment of autoimmune dis ease[J].Autoimmunity,2004,37(5):411-418.
  • 6[4]Guillonneau C,Aubry V,Renaudin K,et al.Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade[J].Transplantation,2005,80(4):546-554.
  • 7[5]BuchnerK,Henn V,Grafe M,et al.CD40 ligand is selectively expressed on CD4+ T cells and platelets:implications for CD40-CD40L signaling in atherosclerosis[J].J Pathol,2003,201(2):288-295.
  • 8[6]Allen SD,Rawale SV,Whitacre CC,et al.Therapeutic pep tidomimetic strategies for autoimmune diseases:costimulation blockade[J].J Pept Res,2005,65(6):591-604.
  • 9[7]Imadome K,Shirakata M,Shimizu N,et al.CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation[J].Proc Natl Acad Sci USA,2003,100(13):7836-7840.
  • 10Girart MV, Fuertes MB, Domaica CI, eta[. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12 [J]. J Immunol, 2007, 179(6):3472-3479.

共引文献4

免疫学杂志
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部